+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide-Drug Conjugates CDMO Service Market - Global Forecast 2026-2032- Product Image
Peptide-Drug Conjugates CDMO Service Market - Global Forecast 2026-2032- Product Image
Sale

Peptide-Drug Conjugates CDMO Service Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6119603
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptide-Drug Conjugates CDMO Service Market is projected to reach USD 357.95 Million in 2026. It is expected to continue growing at a CAGR of 4.80%, reaching USD 480.21 Million by 2032.

Peptide-Drug Conjugate CDMO Services: Executive Summary

Peptide-drug conjugate CDMO services support the design, synthesis, conjugation, purification, analytical characterization, and manufacturing of targeted therapeutics that combine peptide-recognition elements with pharmacologically active payloads. The field sits at the intersection of peptide chemistry, linker and payload engineering, bioconjugation, analytical science, and regulated pharmaceutical production. Demand is shaped by the need for specialized capabilities that can manage complex molecules, protect sensitive intermediates, and provide reproducible quality across development stages.

Specialization and Integration Are Reshaping Development Workflows

The service landscape is shifting from isolated chemistry projects toward integrated development programs. Sponsors increasingly value providers that can connect route development, peptide production, linker-payload coupling, impurity control, formulation, process characterization, and quality documentation within a coordinated workflow. This integration can reduce handoff risks and improve comparability as programs move from discovery into clinical manufacturing.

Other transformative shifts include greater emphasis on site-specific conjugation, scalable solid-phase and liquid-phase synthesis strategies, orthogonal protecting-group schemes, continuous or intensified processing where appropriate, and analytical methods capable of resolving closely related conjugate species. Regulatory expectations are also encouraging earlier attention to critical quality attributes, process control, material traceability, and lifecycle change management.

Artificial Intelligence Is Accelerating Design, Analytics, and Operations

Artificial intelligence is contributing to peptide-drug conjugate development through sequence and property prioritization, prediction of peptide-target interactions, optimization of linker characteristics, and selection of experimental conditions. Machine-learning tools can help organize design spaces and identify relationships among sequence, solubility, stability, conjugation efficiency, and biological activity, although laboratory confirmation remains essential.

AI is also being applied to chromatographic method development, spectral interpretation, batch-trend monitoring, deviation investigation, and production scheduling. Its cumulative value depends on well-curated data, validated workflows, explainable outputs, cybersecurity, and appropriate human oversight. Providers that combine computational tools with disciplined experimental design and compliant data governance are better positioned to improve development speed without weakening quality assurance.

Regional Insights: Capabilities Are Distributed Across Established and Emerging Hubs

North America combines advanced biopharmaceutical development infrastructure, sophisticated analytical capabilities, and strong demand for outsourced complex-molecule manufacturing. Europe offers deep expertise in peptide chemistry, regulated production, and process development, supported by interconnected research and industrial networks. Asia-Pacific is strengthening its role through expanding pharmaceutical manufacturing capacity, specialized chemistry talent, and increasingly sophisticated analytical and quality systems.

Latin America is developing service capabilities alongside broader pharmaceutical and biotechnology ecosystems, with local access, regulatory alignment, and technology transfer remaining important considerations. The Middle East is pursuing life-science diversification and specialized manufacturing partnerships, while Africa’s opportunity is linked to skills development, research infrastructure, and reliable access to high-quality materials and services. Across all regions, sponsor priorities include technical depth, documented quality systems, supply continuity, and the ability to support cross-border regulatory requirements.

Group Insights: Trade, Regulation, and Technical Cooperation Shape Access

ASEAN is characterized by varied manufacturing maturity and regulatory environments, creating opportunities for regional collaboration, technology transfer, and harmonized quality practices. BRICS economies provide broad scientific, industrial, and pharmaceutical capabilities, but cross-border execution can be affected by differing standards, procurement systems, and trade conditions. The European Union benefits from regulatory coordination and integrated research networks, with compliance consistency remaining central to outsourcing decisions.

The G7 combines advanced innovation ecosystems, demanding regulatory expectations, and experienced biopharmaceutical supply chains. GCC countries are emphasizing healthcare localization, investment, and advanced manufacturing partnerships. NATO members collectively include substantial research and manufacturing capacity, although defense-aligned supply-chain priorities do not replace the need for pharmaceutical-specific quality, regulatory, and continuity controls.

Country Insights: National Strengths and Execution Priorities Differ

The United States and Canada offer strong biotechnology ecosystems, specialized analytical expertise, and mature outsourced development practices. Germany, France, Italy, Spain, and the United Kingdom contribute established pharmaceutical research, regulated manufacturing, and technical talent, while European coordination supports cross-border development. Japan and South Korea are distinguished by advanced pharmaceutical technology, precision manufacturing, and high quality-system expectations.

China and India provide extensive chemistry, pharmaceutical manufacturing, and process-development capabilities, with sponsor assessment focused on data integrity, regulatory readiness, intellectual-property protection, and supply-chain resilience. Australia contributes strong research and translational capabilities within a geographically dispersed market. Brazil and Mexico are important Latin American pharmaceutical bases, where local partnerships, regulatory navigation, and dependable logistics influence service selection. Russia’s participation may be constrained by trade, compliance, and access considerations, requiring careful evaluation of applicable restrictions and supply continuity.

Action Priorities for Leaders Building Reliable Conjugate Programs

Industry leaders should qualify partners against demonstrated experience with peptide synthesis, linker-payload chemistry, conjugation control, purification, analytical characterization, and regulated documentation rather than relying on a single capability claim. Technical diligence should examine impurity profiles, batch reproducibility, scalability, method transfer, raw-material controls, and the provider’s ability to preserve molecule integrity during storage and shipment.

Programs should establish critical quality attributes and comparability expectations early, maintain dual-source strategies for strategically important materials where feasible, and use stage-gated development plans that connect nonclinical, clinical, and commercial requirements. Leaders should also define data-governance rules for AI-enabled tools, require transparent model validation, and align contractual responsibilities for deviations, changes, intellectual property, confidentiality, and business continuity.

Research Methodology: Evidence-Based Assessment of Service Capabilities

This executive summary uses a structured assessment of the peptide-drug conjugate CDMO service landscape, focusing on technology requirements, development workflows, quality considerations, regional operating conditions, and organizational groupings. Insights are derived from publicly verifiable sources such as regulatory materials, peer-reviewed scientific literature, official trade and policy publications, pharmaceutical-development disclosures, and documented manufacturing practices.

The analysis distinguishes established capabilities from emerging applications and avoids unsupported numerical claims. Regional, group, and country observations are interpreted through technical infrastructure, regulatory context, research capacity, manufacturing maturity, and supply-chain conditions. Because capabilities and policies evolve, individual providers, facilities, and proposed partnerships should be validated through current technical audits, regulatory reviews, and program-specific due diligence.

Conclusion: Execution Discipline Will Define Competitive Advantage

Peptide-drug conjugate CDMO services are becoming more technically integrated as sponsors seek reliable pathways from molecular design through clinical and regulated manufacturing. Success depends on coordinated expertise across peptide chemistry, conjugation science, purification, analytics, formulation, quality systems, and supply-chain management.

Artificial intelligence can strengthen this ecosystem when applied to high-quality data under validated controls, but it does not replace experimental evidence or regulatory accountability. Organizations that select technically credible partners, plan comparability early, diversify critical inputs, and maintain rigorous oversight will be best positioned to manage the complexity of peptide-drug conjugate development across diverse regional and country environments.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Peptide-Drug Conjugates CDMO Service Market, by Scale Of Operation
7.1. Introduction
7.2. Clinical
7.2.1. Phase I
7.2.2. Phase II
7.2.3. Phase III
7.3. Commercial
7.3.1. Large Scale Manufacturing
7.3.2. Small Scale Manufacturing
7.4. Discovery
7.5. Pilot
8. Peptide-Drug Conjugates CDMO Service Market, by Service Offering
8.1. Introduction
8.2. Analytical Services
8.2.1. Characterization
8.2.2. Release Testing
8.2.3. Stability Testing
8.3. Conjugation
8.3.1. Cleavable Linkers
8.3.2. Noncleavable Linkers
8.4. Formulation
8.4.1. Liquid
8.4.2. Lyophilized
8.5. Peptide Synthesis
8.5.1. Liquid Phase
8.5.2. Solid Phase
8.6. Process Development
8.6.1. Downstream
8.6.2. Upstream
9. Peptide-Drug Conjugates CDMO Service Market, by Peptide Type
9.1. Introduction
9.2. Cyclic
9.3. Linear
9.4. Modified
9.5. Peptidomimetics
10. Peptide-Drug Conjugates CDMO Service Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiovascular
10.2.1. Atherosclerosis
10.2.2. Heart Failure
10.3. Immunology
10.3.1. Autoimmune Diseases
10.3.2. Inflammatory Disorders
10.4. Infectious Disease
10.4.1. Bacterial Infection
10.4.2. Viral Infection
10.5. Oncology
10.5.1. Hematological Malignancies
10.5.2. Solid Tumors
11. Peptide-Drug Conjugates CDMO Service Market, by End User
11.1. Introduction
11.2. Academic
11.3. Biotechnology
11.4. Contract Research Organization
11.5. Government
11.6. Pharmaceutical
12. Peptide-Drug Conjugates CDMO Service Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Peptide-Drug Conjugates CDMO Service Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Peptide-Drug Conjugates CDMO Service Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Aobious, Inc.
16.2. Asymchem, Inc.
16.3. Bachem Holding AG
16.4. BioDuro, Inc.
16.5. Biopeptek, Inc.
16.6. Bio-Synthesis Inc.
16.7. BOC Sciences Ltd.
16.8. Catalent, Inc.
16.9. CordenPharma International GmbH
16.10. Creative Peptides, Inc.
16.11. Evotec SE
16.12. GenScript Biotech Corporation
16.13. JPT Peptide Technologies GmbH
16.14. Lonza Group AG
16.15. Peptide International, Inc.
16.16. Piramal Pharma Solutions
16.17. Polypeptide Group GmbH
16.18. Recipharm AB
16.19. ScinoPharm Taiwan Ltd.
16.20. SN Biopharm Co., Ltd.
16.21. Thermo Fisher Scientific Inc.
16.22. USV Private Limited
16.23. WuXi AppTec Co., Ltd.
16.24. Xinbang Pharma Co., Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Peptide-Drug Conjugates CDMO Service Market, Years Considered for the Study
FIGURE 2. Global Peptide-Drug Conjugates CDMO Service Market, Research Design
FIGURE 3. Global Peptide-Drug Conjugates CDMO Service Market, Research Framework
FIGURE 4. Global Peptide-Drug Conjugates CDMO Service Market, Data Triangulation
FIGURE 5. Global Peptide-Drug Conjugates CDMO Service Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2025 vs 2032 (%)
FIGURE 7. Global Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2025 vs 2032 (%)
FIGURE 9. Global Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2025 vs 2032 (%)
FIGURE 11. Global Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 13. Global Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Peptide-Drug Conjugates CDMO Service Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Peptide-Drug Conjugates CDMO Service Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Peptide-Drug Conjugates CDMO Service Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Peptide-Drug Conjugates CDMO Service Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Peptide-Drug Conjugates CDMO Service Market Segmentation & Coverage
TABLE 2. Global Peptide-Drug Conjugates CDMO Service Market Size, 2017-2032 (USD Million)
TABLE 3. Global Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 4. Global Clinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Clinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Clinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Large Scale Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Large Scale Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Large Scale Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Small Scale Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Small Scale Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Small Scale Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Discovery Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Discovery Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Discovery Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Pilot Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Pilot Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Pilot Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 32. Global Analytical Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Analytical Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Analytical Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Characterization Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Characterization Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Characterization Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Release Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Release Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Release Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Stability Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Stability Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Stability Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Conjugation Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Conjugation Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Conjugation Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Cleavable Linkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Cleavable Linkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Cleavable Linkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Noncleavable Linkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Noncleavable Linkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Noncleavable Linkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Formulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Formulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Formulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Lyophilized Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Lyophilized Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Lyophilized Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Peptide Synthesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Peptide Synthesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Peptide Synthesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Liquid Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Liquid Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Liquid Phase Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Solid Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Solid Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Solid Phase Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Downstream Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Downstream Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Downstream Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Upstream Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Upstream Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Upstream Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 81. Global Cyclic Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Cyclic Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Cyclic Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Linear Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Linear Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Linear Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Modified Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Modified Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Modified Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Peptidomimetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Peptidomimetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Peptidomimetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 94. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Atherosclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Atherosclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Atherosclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Heart Failure Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Heart Failure Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Heart Failure Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Immunology Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Immunology Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Immunology Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Autoimmune Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Autoimmune Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Autoimmune Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Inflammatory Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Inflammatory Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Inflammatory Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Infectious Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Infectious Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Infectious Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Bacterial Infection Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Bacterial Infection Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Bacterial Infection Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Viral Infection Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Viral Infection Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Viral Infection Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. Global Academic Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Academic Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Academic Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Biotechnology Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Biotechnology Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Biotechnology Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Contract Research Organization Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Contract Research Organization Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Contract Research Organization Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Government Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Government Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Government Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Pharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Pharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Pharmaceutical Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 149. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 150. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. North America Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. North America Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 166. North America Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 167. North America Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 168. North America Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 169. North America Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 170. North America Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 171. North America Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 172. North America Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 173. North America Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 174. North America Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 175. North America Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 176. North America Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 177. North America Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 178. North America Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 179. North America Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 180. North America Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 182. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 183. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 184. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 185. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 186. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 187. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 188. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 189. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 190. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 191. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 192. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 193. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 194. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 195. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 196. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 197. Latin America Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 199. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 200. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 201. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 202. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 203. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 204. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 205. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 206. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 207. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 208. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 209. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 210. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 211. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 212. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 213. Europe Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 214. Europe Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 216. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 217. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 218. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 219. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 220. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 221. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 222. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 223. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 224. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 225. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 226. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 227. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 228. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 229. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 230. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 231. Middle East Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 233. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 234. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 235. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 236. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 237. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 238. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 239. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 240. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 241. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 242. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 243. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 244. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 245. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 246. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 247. Africa Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 248. Africa Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. Global Peptide-Drug Conjugates CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 250. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 251. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 252. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 253. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 254. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 255. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 256. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 257. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 258. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 259. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 260. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 261. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 262. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 263. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 264. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 265. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 266. ASEAN Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 268. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 269. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 270. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 271. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 272. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 273. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 274. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 275. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 276. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 277. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 278. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 279. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 280. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 281. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 282. GCC Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 283. GCC Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 285. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 286. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 287. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 288. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 289. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 290. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 291. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 292. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 293. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 294. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 295. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 296. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 297. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 298. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 299. European Union Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 300. European Union Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 302. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 303. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 304. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 305. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 306. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 307. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 308. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 309. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 310. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 311. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 312. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 313. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 314. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 315. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 316. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 317. BRICS Peptide-Drug Conjugates CDMO Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 318. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 319. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Scale Of Operation, 2017-2032 (USD Million)
TABLE 320. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 321. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Commercial, 2017-2032 (USD Million)
TABLE 322. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 323. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 324. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Conjugation, 2017-2032 (USD Million)
TABLE 325. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 326. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Synthesis, 2017-2032 (USD Million)
TABLE 327. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 328. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 329. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 330. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 331. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 332. G7 Peptide-Drug Conjugates CDMO Service Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 333. G7 Peptide-Drug Conjugates

Companies Mentioned

  • Aobious, Inc.
  • Asymchem, Inc.
  • Bachem Holding AG
  • BioDuro, Inc.
  • Biopeptek, Inc.
  • Bio‑Synthesis Inc.
  • BOC Sciences Ltd.
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Creative Peptides, Inc.
  • Evotec SE
  • GenScript Biotech Corporation
  • JPT Peptide Technologies GmbH
  • Lonza Group AG
  • Peptide International, Inc.
  • Piramal Pharma Solutions
  • Polypeptide Group GmbH
  • Recipharm AB
  • ScinoPharm Taiwan Ltd.
  • SN Biopharm Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • USV Private Limited
  • WuXi AppTec Co., Ltd.
  • Xinbang Pharma Co., Ltd.

Related Topics

Related Reports

Peptide Drug CDMO Market - Global Forecast 2026-2032 - Product Image

Peptide Drug CDMO Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Antibody-Oligonucleotide Conjugates Drug CDMO Market - Global Forecast 2026-2032 - Product Image

Antibody-Oligonucleotide Conjugates Drug CDMO Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Pharmaceutical CDMO 2.0 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Pharmaceutical CDMO 2.0 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Outlook 2026-2034: Market Share, and Growth Analysis by Product (Peptide CDMO, Oligonucleotide CDMO, Peptide-Oligonucleotide Conjugate CDMO), Application, Service Type, End User - Product Image

Peptide and Oligonucleotide CDMO Market Outlook 2026-2034: Market Share, and Growth Analysis by Product (Peptide CDMO, Oligonucleotide CDMO, Peptide-Oligonucleotide Conjugate CDMO), Application, Service Type, End User

  • Report
  • 160 Pages
  • Global
From
Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.